Britain and America have announced a key trade agreement that will preserve zero tariffs on British pharmaceutical exports entering the US market.
The Terms of the Accord
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial exports will remain at nothing for a period of 36 months.
This agreement is in response to previous warnings to hike duties on branded pharmaceutical imports, with figures mentioned up to double the cost.
"This arrangement between the UK reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to transatlantic medicine commerce," an announcement declared.
Economic Significance
Drugs are one of the UK's most significant exports to the US, which is by far the biggest destination for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of September, the UK exported medicines valued at billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This agreement secures employment, stimulates capital expenditure and facilitates the UK to emerge as a international leader for medical research," a minister commented.
Key UK Commitments
The pact involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to stay within budget will be restricted at 15%. In the past, refunds exceeded twenty percent.
Broader Context
The deal takes place against a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that US customers were charged significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been paused or cancelled, while major expansions have been announced toward projects in the United States.
One official stated that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
